Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

FDA Approves Atezolizumab with Nab-paclitaxel and Carboplatin for Metastatic NSCLC without EGFR/ALK Aberrations

Oncology Practice Insider

On December 3, 2019, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Read more.